CL2019002566A1 - Anticuerpos anti-phf-tau y usos de estos. - Google Patents

Anticuerpos anti-phf-tau y usos de estos.

Info

Publication number
CL2019002566A1
CL2019002566A1 CL2019002566A CL2019002566A CL2019002566A1 CL 2019002566 A1 CL2019002566 A1 CL 2019002566A1 CL 2019002566 A CL2019002566 A CL 2019002566A CL 2019002566 A CL2019002566 A CL 2019002566A CL 2019002566 A1 CL2019002566 A1 CL 2019002566A1
Authority
CL
Chile
Prior art keywords
antibodies
phf
tau antibodies
tau
tauopathies
Prior art date
Application number
CL2019002566A
Other languages
English (en)
Inventor
Marc Mercken
Thomas Malia
Marianne Borgers
Kolen Kristof Van
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CL2019002566A1 publication Critical patent/CL2019002566A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Abstract

SE DESCRIBEN ANTICUERPOS MONOCLONALES ANTI-PHF-TAU Y FRAGMENTOS DE UNIÓN AL ANTÍGENO DE ESTOS. ADEMÁS, SE DESCRIBEN ÁCIDOS NUCLEICOS QUE CODIFICAN LOS ANTICUERPOS, COMPOSICIONES QUE COMPRENDEN LOS ANTICUERPOS, MÉTODOS PARA PRODUCIR LOS ANTICUERPOS Y USAR LOS ANTICUERPOS PARA TRATAR O PREVENIR AFECCIONES, TALES COMO TAUOPATÍAS.
CL2019002566A 2017-03-16 2019-09-09 Anticuerpos anti-phf-tau y usos de estos. CL2019002566A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762472214P 2017-03-16 2017-03-16

Publications (1)

Publication Number Publication Date
CL2019002566A1 true CL2019002566A1 (es) 2019-12-27

Family

ID=63521020

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002566A CL2019002566A1 (es) 2017-03-16 2019-09-09 Anticuerpos anti-phf-tau y usos de estos.

Country Status (21)

Country Link
US (3) US10766953B2 (es)
EP (1) EP3596119A4 (es)
JP (2) JP7159185B2 (es)
KR (2) KR102597462B1 (es)
CN (2) CN110799531B (es)
AR (1) AR111288A1 (es)
AU (1) AU2018234709A1 (es)
BR (3) BR112019019049A2 (es)
CA (1) CA3055598A1 (es)
CL (1) CL2019002566A1 (es)
EA (1) EA201992038A1 (es)
IL (2) IL310464A (es)
JO (1) JOP20180021A1 (es)
MA (1) MA47789A (es)
MX (1) MX2019010922A (es)
PH (1) PH12019501973A1 (es)
SG (1) SG11201907754RA (es)
TW (1) TWI771389B (es)
UY (1) UY37635A (es)
WO (1) WO2018170351A1 (es)
ZA (1) ZA202101318B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20152004A1 (es) 2013-03-13 2016-02-07 Prothena Biosciences Ltd Inmunoterapia tau
KR102506091B1 (ko) 2016-05-02 2023-03-07 프로테나 바이오사이언시즈 리미티드 타우 면역요법
CU24537B1 (es) 2016-05-02 2021-07-02 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
AU2018263935A1 (en) 2017-05-02 2019-12-19 Prothena Biosciences Limited Antibodies recognizing tau
TW202340244A (zh) 2017-10-16 2023-10-16 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
JP2022524588A (ja) 2019-03-03 2022-05-09 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
BR112021021062A2 (pt) * 2019-05-31 2021-12-14 Lilly Co Eli Compostos e métodos que alvejam tau humano
AU2020325770B2 (en) * 2019-08-06 2022-08-25 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
PE20230385A1 (es) * 2020-04-08 2023-03-06 Janssen Biotech Inc Anticuerpos anti-phf-tau y usos de estos
JP2023533806A (ja) * 2020-07-14 2023-08-04 ヤンセン ファーマシューティカ エヌ．ベー． タウオパチー又はアミロイド形成疾患を検出するための血液ベースのアッセイ
JP2023546503A (ja) * 2020-10-26 2023-11-02 ヤンセン ファーマシューティカ エヌ．ベー． 抗タウ抗体の安全な投与方法
US20220127345A1 (en) * 2020-10-26 2022-04-28 Janssen Pharmaceutica Nv Methods of Reducing Tau in Human Subjects
BR112023014151A2 (pt) * 2021-02-19 2023-10-10 Eisai R&D Man Co Ltd Anticorpo tau anti-pt217
CA3214310A1 (en) 2021-03-26 2022-09-29 Rupesh Nanjunda Anti-tau antibodies and uses thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
CN116948023B (zh) * 2023-09-14 2024-02-09 北京凯祥弘康生物科技有限公司 Tau蛋白抗体及其应用
CN116948024B (zh) * 2023-09-14 2024-02-06 北京凯祥弘康生物科技有限公司 抗Tau蛋白的捕获抗体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
JP3909084B2 (ja) 1991-10-25 2007-04-25 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 微小管結合タンパク質タウに対するモノクローナル抗体
EP0737208B1 (en) * 1993-12-21 2006-08-02 Innogenetics N.V. Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications
JPH10506381A (ja) 1994-07-29 1998-06-23 イノジェネティックス・ナムローゼ・フェンノートシャップ 特定のサブクラスまたは形態のホスホリレーションされたｔａｕのエピトープに特異的なモノクローナル抗体、それらを分泌するハイブリドーマ、これらの抗体の抗原認識およびそれらの応用
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
ES2567198T3 (es) 2003-01-24 2016-04-20 Applied Molecular Evolution, Inc. Antagonistas de la IL-1 beta humana
EP1697741A4 (en) 2003-12-04 2008-02-13 Xencor Inc PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF
WO2005079479A2 (en) * 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
KR101437188B1 (ko) 2006-08-04 2014-10-02 노바르티스 아게 Ｅｐｈｂ3-특이적 항체 및 이의 용도
JP2010235447A (ja) 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
US20100261620A1 (en) 2008-10-14 2010-10-14 Juan Carlos Almagro Methods of Humanizing and Affinity-Maturing Antibodies
JP2012508017A (ja) * 2008-11-07 2012-04-05 ファブラス エルエルシー 抗ｄｌｌ４抗体及びその使用
US9968574B2 (en) 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
CA2765099A1 (en) 2009-06-10 2010-12-16 New York University Phosphorylated tau peptide for use in the treatment of tauopathy
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US8912355B2 (en) 2009-09-29 2014-12-16 University Of Ottawa Heart Institute Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes
WO2011047146A2 (en) 2009-10-14 2011-04-21 Centocor Ortho Biotech Inc. Methods of affinity maturing antibodies
BR112012025730B1 (pt) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
CN103502272B (zh) 2010-10-07 2016-06-15 Ac免疫有限公司 识别Tau的磷酸化特异抗体
SI2627672T1 (sl) 2010-10-11 2018-10-30 Biogen International Neuroscience Gmbh Človeška protitelesa anti-tau
MY186066A (en) * 2011-12-20 2021-06-18 Janssen Biotech Inc Anti-phf-tau antibodies and their uses

Also Published As

Publication number Publication date
US20230047413A1 (en) 2023-02-16
BR122023021947A2 (pt) 2024-02-20
MX2019010922A (es) 2019-11-08
EP3596119A4 (en) 2021-01-13
JP2020513804A (ja) 2020-05-21
EP3596119A1 (en) 2020-01-22
JP7159185B2 (ja) 2022-10-24
IL310464A (en) 2024-03-01
US20210179696A1 (en) 2021-06-17
MA47789A (fr) 2020-01-22
IL268700B1 (en) 2024-03-01
TWI771389B (zh) 2022-07-21
CA3055598A1 (en) 2018-09-20
PH12019501973A1 (en) 2020-06-29
US11365244B2 (en) 2022-06-21
AR111288A1 (es) 2019-06-26
JOP20180021A1 (ar) 2019-01-30
WO2018170351A8 (en) 2019-12-19
JP2022191383A (ja) 2022-12-27
WO2018170351A1 (en) 2018-09-20
CN110799531B (zh) 2023-08-04
KR102597462B1 (ko) 2023-11-03
BR122023021958A2 (pt) 2024-02-20
BR112019019049A2 (pt) 2020-04-22
ZA202101318B (en) 2023-03-29
KR20230155025A (ko) 2023-11-09
CN117209599A (zh) 2023-12-12
TW201900682A (zh) 2019-01-01
CN110799531A (zh) 2020-02-14
US20180265575A1 (en) 2018-09-20
IL268700A (en) 2019-10-31
AU2018234709A1 (en) 2019-08-29
EA201992038A1 (ru) 2020-02-06
UY37635A (es) 2018-09-28
SG11201907754RA (en) 2019-09-27
US10766953B2 (en) 2020-09-08
KR20190130133A (ko) 2019-11-21

Similar Documents

Publication Publication Date Title
CL2019002566A1 (es) Anticuerpos anti-phf-tau y usos de estos.
CO2020014575A2 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
ECSP20082991A (es) Agentes aglutinantes del psma y usos de estos
ECSP18041833A (es) Anticuerpos que se unen específicamente a pd-1 y sus usos
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
CR20170079A (es) Agentes de unión a cd123 y usos de estos
AR093394A1 (es) Anticuerpos especificos del factor de crecimiento b derivado de plaquetas (pdgf-b), composiciones y usos de estos
CO2018012513A2 (es) Anticuerpos
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
AR108975A1 (es) Anticuerpos con baja inmunogenicidad y sus usos
DOP2022000218A (es) Anticuerpos anti-phf-tau y usos de estos
EA201890434A1 (ru) Антитела к cd154 и способы их применения
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas
ECSP17080733A (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
UY39699A (es) Anticuerpos anti-tau y usos de estos
EA202092122A1 (ru) Антитела против tip-1 и их применения
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.
DOP2021000229A (es) Materiales y métodos para modular la inmunidad mediada por cédula t